Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.

El-Gazzar A, Perco P, Eckelhart E, Anees M, Sexl V, Mayer B, Liu Y, Mikulits W, Horvat R, Pangerl T, Zheng D, Krainer M.

Mol Cancer Ther. 2010 Apr;9(4):1007-18. doi: 10.1158/1535-7163.MCT-09-0933. Epub 2010 Apr 6.

2.

Linking the ovarian cancer transcriptome and immunome.

Rapberger R, Perco P, Sax C, Pangerl T, Siehs C, Pils D, Bernthaler A, Lukas A, Mayer B, Krainer M.

BMC Syst Biol. 2008 Jan 3;2:2. doi: 10.1186/1752-0509-2-2.

3.

Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R.

Curr Pharm Des. 2002;8(20):1781-807. Review.

PMID:
12171531
4.

Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells.

Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, Baumgartner G, Dudczak R, Virgolini I.

J Nucl Med. 2001 Dec;42(12):1856-62.

5.

111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung.

Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fueger BJ, Schima W, Kurtaran A, Dudczak R, Virgolini I.

J Nucl Med. 2001 Sep;42(9):1309-15.

6.

New trends in peptide receptor radioligands.

Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R.

Q J Nucl Med. 2001 Jun;45(2):153-9. Review.

PMID:
11476164
7.

New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.

Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtaran A, Niederle B, Dudczak R.

Q J Nucl Med. 2000 Mar;44(1):50-8. Review.

PMID:
10932601
8.

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.

Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I.

Endocrinology. 1999 Nov;140(11):5136-48.

PMID:
10537142
9.

Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type.

Raderer M, Valencak J, Pfeffel F, Drach J, Pangerl T, Kurtaran A, Hejna M, Vorbeck F, Chott A, Virgolini I.

J Natl Cancer Inst. 1999 Apr 21;91(8):716-8. No abstract available.

PMID:
10218510
10.

Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo.

Raderer M, Pangerl T, Leimer M, Valencak J, Kurtaran A, Hamilton G, Scheithauer W, Virgolini I.

J Natl Cancer Inst. 1998 Nov 4;90(21):1666-8. No abstract available.

PMID:
9811317
11.

Visualization of intestinal splenosis by somatostatin receptor scintigraphy.

Kurtaran A, Pangerl T, Scheuba C, Schima W, Schober E, Kaserer K, Teleky B, Virgolini I.

Am J Gastroenterol. 1998 Aug;93(8):1375-6. Review.

PMID:
9707072
12.

Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.

Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R.

Cancer Res. 1998 May 1;58(9):1850-9.

13.

Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer?

Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M.

Eur J Clin Invest. 1997 Aug;27(8):645-7. Review. No abstract available.

PMID:
9279526

Supplemental Content

Loading ...
Support Center